OBJECTIVE： To investigate the status quo and tendency of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015. METHODS： The prescriptions of breast cancer patients in 11 hospitals of Zhejiang province were analyzed retrospectively in respects of consumption sum， DDDs， DDC， etc. RESULTS： The consumption sum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 increased from 2 530 192.33 yuan to 6 201 691.54 yuan， and its proportion in total consumption sum increased from 13.93％ to 17.40％， showing increasing tendency. The anastrozole always took up the first place in the list of consumption sum. Tamoxifen， anastrozole and letrozole took up the top 3 places in the list of DDDs. Goserelin took up the first place in the list of DDC. CONCLUSIONS： The prescription amount and consumptionsum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 show year-on-year growth trend； and those drugs which are safe， effective， economical and convenient predominate in clinic.